View All Immuno-Oncology Resources

Advanced Practice Providers (APPs), such as nurse practitioners and physician assistants, play a fundamental role within medical oncology departments and the care of patients with cancer.

Learn about the key proposals in the CY 2023 Medicare Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System (OPPS) proposed rules and how these proposed changes to Medicare payment will impact oncology practices, freestanding cancer centers, and hospital-based cancer programs in 2023. There will be an opportunity for live Q&A.Speakers: Teri Bedard, BA, RT(R)(T), CPCExecutive …

Oncodermatology is a rapidly developing field that is attracting significant interest and generating new literature in the context of cancer treatment strategies.

The non-specific adverse events of immune-based therapies, which often mimic autoimmune disorders rather than traditional cytotoxic effects, pose a significant challenge to emergency medicine providers.

Caring for patients experiencing toxicities from treatment with immune checkpoint inhibitors (ICIs) requires multidisciplinary input and coordination. Rheumatologists evaluate and treat patients experiencing a wide variety of immune-related adverse events (irAEs), including inflammatory arthritis, sicca syndrome, polymyalgia rheumatica, myositis, vasculitis, and scleroderma. It’s important for rheumatologists …

While immuno-oncology (IO) therapies have heralded significant advancements in cancer care, there are still many unknowns when it comes to the long-term side effects of these relatively new agents. Since ambulatory care typically involves long-term chronic disease management, these unknowns can often translate to management uncertainty.

The positive impacts of IO therapy are remarkable, the era of IO has also ushered in new challenges. The efficacy of IO has led to a growing population of patients living with and beyond cancer. This has challenged original concepts of survivorship care, starting with the very definition of “survivorship.”

Envision a day that cancer clinicians can ask an app to advise on immuno-oncology (IO) treatment options for a patient. That day may not be far off. Big data, deep analytics, and predictive modeling methods are transforming how cancer clinicians weigh treatment options.

SARS-CoV-2 and the resulting respiratory tract infection COVID-19 has upended our society and forcefully changed the way we care for patients. Since the emergence of the virus in early 2020, there have been questions surrounding the risk posed to patients with a cancer diagnosis and the safety of anticancer therapies.

Presented at the SITC Annual Conference.

Presented at the 2020 JADPRO Live Virtual Meeting.

Through its immunotherapy initiative, ACCC has developed a medical wallet card for patients on immunotherapy for cancer. A downloadable print-ready PDF enables cancer programs & practices to have copies printed.

In this newly published IO Whitepaper, we take a forward look at how the ACCC IO Institute meets the needs of the evolving multidisciplinary cancer care team and other interdisciplinary providers who may be involved in caring for patients treated with immunotherapies for cancer.

Tammy Turner, Executive Director, Community Cancer Center, and Nancy Laney, President, Laney IT Consulting, discuss the most important strategies for planning, building, and implementing a telehealth program. (April 16, 2020)

Teri Bedard, BA, RT(R)(T), CPC, Director, Client Services, Revenue Cycle Coding Strategies LLC discusses CMS’ changes to telehealth coding and billing in response to the COVID-19 public health emergency, includes Q&A. (April 9, 2020)

ACCC’s Immuno-Oncology Institute has developed the Survivorship Care Plans for Patients Receiving Immunotherapy as a resource for cancer programs and practices. and describes processes for developing survivorship care plans (SCPs) for patients treated with immunotherapy, effective practices in SCP design, and considerations for SCP delivery for this patient population.

Learn about the transition from immunotherapy into post-treatment survivorship, how it differs from chemotherapy, and why coordination and communication among providers, patients, and caregivers is essential.

Our busy community practice first began treating patients with immunotherapy through participating in the original ipilimumab clinical trials. We quickly realized that this new treatment paradigm would require us to create and implement an effective screening and management tool for our immunooncology (IO) patient population.

Immuno-oncology (IO) has radically altered the patient care paradigm. One of most important changes attributed to IO is improvement in outcomes and lengthening of survival. This good news comes with multiple challenges, not least of which is the need for new and better communication and coordination among multiple specialties over time.

Immune-related adverse events (irAEs) are extremely common in patients being treated with checkpoint inhibitors for advanced melanoma. The type, quality, and severity of these adverse events, however, varies by treatment regimen and by patient.